Dual-template rectangular nanotube molecularly imprinted polypyrrole for label-free impedimetric sensing of AFP and CEA as lung cancer biomarkers

Talanta ◽  
2021 ◽  
pp. 123146
Author(s):  
Navid Taheri ◽  
Hosein Khoshsafar ◽  
Mostafa Ghanei ◽  
Ali Ghazvini ◽  
Hasan Bagheri
Keyword(s):  
Lung Cancer ◽  
Cancer Biomarkers ◽  
Label Free ◽  
Molecularly Imprinted

scholarly journals PTRF/Cavin-1 and MIF Proteins Are Identified as Non-Small Cell Lung Cancer Biomarkers by Label-Free Proteomics

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e33752 ◽  
Author(s):  
Angelo Gámez-Pozo ◽  
Iker Sánchez-Navarro ◽  
Enrique Calvo ◽  
María Teresa Agulló-Ortuño ◽  
Rocío López-Vacas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cancer Biomarkers ◽  
Small Cell ◽  
Label Free ◽  
Small Cell Lung

scholarly journals “Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Brett C. Bade ◽  
Geliang Gan ◽  
Fangyong Li ◽  
Lingeng Lu ◽  
Lynn Tanoue ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Physical Activity ◽  
Lung Cancer ◽  
Randomized Trial ◽  
Cancer Biomarkers ◽  
Advanced Stage ◽  
Home Based ◽  
Advanced Stage Lung Cancer ◽  
Stage Lung Cancer

Abstract Background Lung cancer survivors need more options to improve quality of life (QoL). It is unclear to what extent patients with advanced stage disease are willing to participate in home-based physical activity (PA) and if these interventions improve QoL. The goal of our study was to determine interest in participating in our 3-month home-based walking regimen in patients with advanced stage lung cancer. We used a randomized design to evaluate for potential benefit in PA and patient-reported outcomes. Methods We performed an open-label, 1:1 randomized trial in 40 patients with stage III/IV non-small cell lung cancer (NSCLC) evaluating enrollment rate, PA, QoL, dyspnea, depression, and biomarkers. Compared to usual care (UC), the intervention group (IG) received an accelerometer, in-person teaching session, and gain-framed text messages for 12 weeks. Results We enrolled 56% (40/71) of eligible patients. Participants were on average 65 years and enrolled 1.9 years from diagnosis. Most patients were women (75%), and receiving treatment (85%) for stage IV (73%) adenocarcinoma (83%). A minority of patients were employed part-time or full time (38%). Both groups reported low baseline PA (IG mean 37 (Standard deviation (SD) 46) vs UC 59 (SD 56) minutes/week; p = 0.25). The IG increased PA more than UC (mean change IG + 123 (SD 212) vs UC + 35 (SD 103) minutes/week; p = 0.051)). Step count in the IG was not statistically different between baseline (4707 step/day), week 6 (5605; p = 0.16), and week 12 (4606 steps/day; p = 0.87). The intervention improved EORTC role functioning domain (17 points; p = 0.022) with borderline improvement in dyspnea (− 13 points; p = 0.051) compared to UC. In patients with two blood samples (25%), we observed a significant increase in soluble PD-1 (219.8 (SD 54.5) pg/mL; p < 0.001). Conclusions Our pilot trial using a 3-month, home-based, mobile health intervention enrolled over half of eligible patients with stage III and IV NSCLC. The intervention increased PA, and may improve several aspects of QoL. We also identified potential biomarker changes relevant to lung cancer biology. Future research should use a larger sample to examine the effect of exercise on cancer biomarkers, which may mediate the association between PA and QoL. Clinical trial registration Clinicaltrials.gov (NCT03352245).

scholarly journals Label-Free Detection of Human Serum Using Surface-Enhanced Raman Spectroscopy Based on Highly Branched Gold Nanoparticle Substrates for Discrimination of Non-Small Cell Lung Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-13
Author(s):  
Xiaowei Cao ◽  
Zhenyu Wang ◽  
Liyan Bi ◽  
Jie Zheng
Keyword(s):  
Lung Cancer ◽  
Raman Spectroscopy ◽  
Cell Lung Cancer ◽  
Surface Enhanced Raman Spectroscopy ◽  
Small Cell ◽  
Label Free ◽  
Small Cell Lung ◽  
Surface Enhanced ◽  
Different Types ◽  
Surface Enhanced Raman

Surface-enhanced Raman spectroscopy (SERS) is a good candidate for the development of fast and easy-to-use diagnostic tools, possibly used on serum in screening tests. In this study, a potential label-free serum test based on SERS spectroscopy was developed to analyze human serum for the diagnosis of the non-small cell lung cancer (NSCLC). We firstly synthesized novel highly branched gold nanoparticles (HGNPs) at high yield through a one-step reduction of HAuCl4 with dopamine hydrochloride at 60°C. Then, HGNP substrates with good reproducibility, uniformity, and high SERS effect were fabricated by the electrostatically assisted (3-aminopropyl) triethoxysilane-(APTES-) functionalized silicon wafer surface-sedimentary self-assembly method. Using as-prepared HGNP substrates as a high-performance sensing platform, SERS spectral data of serum obtained from healthy subjects, lung adenocarcinoma patients, lung squamous carcinoma patients, and large cell lung cancer patients were collected. The difference spectra among different types of NSCLC were compared, and analysis result revealed their intrinsic difference in types and contents of nucleic acids, proteins, carbohydrates, amino acids, and lipids. SERS spectra were analyzed by principal component analysis (PCA), which was able to distinguish different types of NSCLC. Considering its time efficiency, being label-free, and sensitivity, SERS based on HGNP substrates is very promising for mass screening NSCLC and plays an important role in the detection and prevention of other diseases.

scholarly journals Circulating or tissue microRNAs and extracellular vesicles as potential lung cancer biomarkers: a systematic review

2017 ◽  
Vol 33 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Yan Song ◽  
Xiuli Yu ◽  
Zongmei Zang ◽  
Guijuan Zhao
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Extracellular Vesicles ◽  
Target Genes ◽  
Enrichment Analysis ◽  
Cancer Biomarkers ◽  
Biological Processes ◽  
Lung Cancer Patients ◽  
Prediction Of Prognosis

For both lung cancer patients and clinical physicians, tumor biomarkers for more efficient early diagnosis and prediction of prognosis are always wanted. Biomarkers in circulating serum, including microRNAs (miRNAs) and extracellular vesicles, hold the greatest possibilities to partially substitute for tissue biopsy. In this systematic review, studies on circulating or tissue miRNAs and extracellular vesicles as potential biomarkers for lung cancer patients were reviewed and are discussed. Furthermore, the target genes of the miRNAs indicated were identified through the miRTarBase, while the relevant biological processes and pathways of miRNAs in lung cancer were analyzed through MiRNA Enrichment Analysis and Annotation (MiEAA). In conclusion, circulating or tissue miRNAs and extracellular vesicles provide us with a window to explore strategies for diagnosing and assessing prognosis and treatment in lung cancer patients.

MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis

2013 ◽  
Vol 46 (10-11) ◽  
pp. 918-925 ◽  
Author(s):  
Ivan Vannini ◽  
Francesca Fanini ◽  
Muller Fabbri
Keyword(s):  
Lung Cancer ◽  
Cancer Biomarkers ◽  
Lung Carcinogenesis ◽  
Key Players

scholarly journals An Aptamer-Based Capacitive Sensing Platform for Specific Detection of Lung Carcinoma Cells in the Microfluidic Chip

Biosensors ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. 98 ◽  
Author(s):  
Ngoc-Viet Nguyen ◽  
Chun-Hao Yang ◽  
Chung-Jung Liu ◽  
Chao-Hung Kuo ◽  
Deng-Chyang Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Carcinoma ◽  
Early Stage ◽  
A549 Cells ◽  
Microfluidic Channel ◽  
Electrical Impedance Spectroscopy ◽  
Label Free ◽  
Early Stage Lung Cancer ◽  
Sensing Platform ◽  
Label Free Detection

Improvement of methods for reliable and early diagnosis of the cellular diseases is necessary. A biological selectivity probe, such as an aptamer, is one of the candidate recognition layers that can be used to detect important biomolecules. Lung cancer is currently a typical cause of cancer-related deaths. In this work, an electrical sensing platform is built based on amine-terminated aptamer modified-gold electrodes for the specific, label-free detection of a human lung carcinoma cell line (A549). The microdevice, that includes a coplanar electrodes configuration and a simple microfluidic channel on a glass substrate, is fabricated using standard photolithography and cast molding techniques. A procedure of self-assembly onto the gold surface is proposed. Optical microscope observations and electrical impedance spectroscopy measurements confirm that the fabricated microchip can specifically and effectively identify A549 cells. In the experiments, the capacitance element that is dominant in the change of the impedance is calculated at the appropriate frequency for evaluation of the sensitivity of the biosensor. Therefore, a simple, inexpensive, biocompatible, and selective biosensor that has the potential to detect early-stage lung cancer would be developed.

Sign in / Sign up

Export Citation Format

Share Document